Oncolytics Biotech Promotes John McAdory To COO
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Oncolytics Biotech Announces Initial Data From Preclinical Study Supporting Further Evaluation Of Pelareorep In Combination With RAS Inhibitor Modalities In Solid Tumor Model
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $10 Price Target
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
ONCY: Aligns with FDA on Pivotal Trial for Pelareorep in Anal Cancer
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Oncolytics Biotech Announces Its Data From REO 022 Trial In Metastatic Colorectal Cancer Shows 19.5-Month Median Duration Of Response In Second-Line KRAS-Mutant MSS mCRC Participants
CEO Chat with Jared Kelly, CEO of Oncolytics Biotech
Oncolytics Biotech Aligns With FDA On Pivotal Trial Design For Pelareorep In Advanced Anal Cancer
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths
ONCY: Initiating Coverage of Oncolytics Biotech; A Focused Path to Unlocking the Potential of Pelareorep
CORRECTION: Oncolytics Biotech Launches Up To $75M At-the-Market Equity Offering With Jefferies To Fund Clinical Development And Operations
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Oncolytics Biotech Schedules FDA Type C Meeting On April 16
Oncolytics Biotech’s Nevada Move Resets Capital Access And Dilution Trade Off
Oncolytics Biotech® Completes Domicile Change to the United States
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
